Increased prolactin response to buspirone in chronic fatigue syndrome.
We studied the endocrine and subjective responses that followed acute administration of the 5-HT1A receptor agonist buspirone (0.5 mg/kg orally) in 11 male patients with chronic fatigue syndrome (CFS) and a group of matched healthy controls. Patients with CFS had significantly higher plasma prolactin concentrations and experienced more nausea in response to buspirone than did controls. However, the growth hormone response to buspirone did not distinguish CFS patients from controls. Our data question whether the enhancement of buspirone-induced prolactin release in CFS is a consequence of increased sensitivity of post-synaptic 5-HT1A receptors. It is possible that the increased prolactin response to buspirone in CFS could reflect changes in dopamine function.
Sharpe
M
M
University Department of Psychiatry, Warneford and Littlemore Hospitals, Oxford, UK.
Clements
A
A
Hawton
K
K
Young
A H
AH
Sargent
P
P
Cowen
P J
PJ
D000293:Adolescent; D000328:Adult; D002065:Buspirone / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D015673:Fatigue Syndrome, Chronic / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood* / Q000378:metabolism*; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use*
D017366:Serotonin Receptor Agonists; D011388:Prolactin; D002065:Buspirone